Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Please cancel claims 1 to 55 without prejudice or disclaimer.

Please add new claims 56 to 87 as follows:

Claims 1 to 55 (cancelled)

56. (new): A cDNA-RNA hybrid comprising a first strand cDNA synthesis hybridised to RNA wherein the cDNA comprises from the 5'end, an amplifier sequence, 3' to which is an RNA polymerase promoter operably linked to an RNA annealing region, and wherein at least one non-templated nucleotide at the 3' end of the first strand cDNA is hybridised to a template switching oligonucleotide, and wherein the amplifier sequence and the template switching oligonucleotide contain the same sequence.

57. (new): A cDNA-RNA hybrid according to claim 56 wherein the RNA polymerase promoter is a bacteriophage promoter selected from the group consisting of T7, T3 and SP6.

58. (new): A cDNA-RNA hybrid according to claim 56 wherein the RNA annealing region comprises poly (dT) of about 10 to about 30 T residues in length.

59. (new): A cDNA-RNA hybrid according to claim 56 wherein the 3' end of the RNA annealing region comprises a VN clamp, wherein V is A, G or C and N is A, G, C or T.

60. (new): A cDNA-mRNA hybrid according to claim 56 wherein at least one non-templated nucleotide at the 3' end of the first strand cDNA synthesis is deoxycytidine.

61. (new): A cDNA-mRNA hybrid according to claim 56 wherein at least three non-templated nucleotide at the 3' end of the first strand cDNA synthesis are hybridised to a template switching oligonucleotide.

62. (new): A cDNA-mRNA hybrid according to claim 56 wherein at least three of the non-templated nucleotides at the 3' end of the first strand cDNA synthesis are deoxycytidine nucleotides.

63. (new): A cDNA-mRNA hybrid according to claim 56 wherein the template switching oligonucleotide has at least three guanine residues at its 3' end.

64. (new): A cDNA-mRNA hybrid according to claim 56 further comprising an amplification primer and wherein, the amplification primer contains the same sequence as the amplifier sequence and the template switching oligonucleotide.

65. (new): A cDNA-mRNA hybrid according to claim 56 wherein the 3' end of the first strand cDNA synthesis is extended such that it is substantially complementary to the template switching oligonucleotide.

66. (new): A cDNA-mRNA hybrid according to claim 65 wherein the first strand cDNA synthesis is synthesised by a reverse transcriptase, and wherein the reverse transcriptase lacks RNaseH activity but retains wild-type polymerase activity.

67. (new): A method for amplifying RNA in a sample comprising the steps of:

(a) providing a cDNA synthesis oligonucleotide comprising from the 5' end, an amplifier sequence 3' to which is an RNA polymerase promoter operably linked to an RNA annealing region;

(b) annealing the RNA annealing region of the cDNA synthesis oligonucleotide to

RNA under suitable conditions to produce a cDNA-RNA complex;

(c) incubating said cDNA-RNA complex under conditions which permit template-dependent extension of the cDNA synthesis oligonucleotide to generate an cDNA-RNA hybrid;

(d) contacting said cDNA-mRNA hybrid with a template switching oligonucleotide under conditions which permit template dependent extension of said cDNA, such that the 3' end of the cDNA comprises a sequence complementary to said template switching oligonucleotide, wherein the amplifier sequence and the template switching oligonucleotide contain the same sequence;

(e) providing an amplification primer under conditions to generate double stranded amplification products corresponding to the first strand cDNA synthesis, such that the cDNA amplification products comprise a double stranded RNA polymerase promoter; and

(f) incubating said cDNA amplification products comprising said double stranded RNA polymerase promoter under conditions that permit *in vitro* transcription to generate amplified RNA.

68. (new): A method according to claim 67 wherein said cDNA-RNA hybrid is incubated with a reverse transcriptase that adds at least one deoxycytidine residue to the 3' end of the first strand cDNA synthesis.

69. (new): A method according to claim 67 or claim 68 wherein at least three non-templated nucleotide at the 3' end of the first strand cDNA synthesis are hybridised to a template switching oligonucleotide.

70. (new): A method according to claim 69 wherein at least three of the non-templated nucleotides at the 3' end of the first strand cDNA synthesis are deoxycytidine residues.

71. (new): A method according to claim 70 wherein the reverse transcriptase lacks RNaseH activity but retains wild-type polymerase activity.

72. (new): A method according to claim 71 wherein said template switching oligonucleotide comprises at least three ribonucleotide residues.

73. (new): A method according to claim 72 wherein said template switching oligonucleotide comprises at least three guanine residues.

74. (new): A method according to claim 73 wherein said amplification primer has the same sequence as the amplifier sequence of said cDNA synthesis oligonucleotide.

75. (new): A method according to claim 74 wherein the double stranded amplification products are obtained by PCR.

76. (new): A method according to claim 75 wherein the cDNA synthesis oligonucleotide and the PCR primer have the same concentration

77. (new): A method according to claim 76 wherein the optimum number of cycles to generate the double stranded amplification products is determined by a method comprising the steps of:

(a) providing a plurality of samples with a known amount of RNA;

(b) performing amplification for a defined number of cycles on the plurality of samples;

(c) purifying the double stranded amplification products;

(d) providing for the *in vitro* transcription of the purified amplification products; and

(e) determining the number of amplification cycles that results in the minimum amount of amplified RNA that is required.

78. (new): A method according to claim 77 wherein the RNA sample is a clinical sample selected from the group consisting of a biopsy, a microdissected tissue, a fine needle aspirate, a flow-sorted cell, a laser captured microdissected cell or a single cell.

79. (new): A method for preparing an expression library of a cell or a cell population comprising the steps of:

(a) providing a cDNA synthesis oligonucleotide comprising from the 5' end, an amplifier sequence, 3' to which is an RNA polymerase promoter operably linked to an RNA annealing region;

(b) contacting said cDNA synthesis oligonucleotide with a population of mRNAs from said cell or cell population under conditions to allow hybridisation of said cDNA synthesis oligonucleotide to mRNA to produce a cDNA-mRNA complex;

(c) incubating said cDNA-mRNA complex under conditions which permit template-dependent extension of said cDNA synthesis oligonucleotide to generate a cDNA-mRNA hybrid;

(d) contacting said cDNA-mRNA hybrid with a template switching oligonucleotide under conditions which permit template dependent extension of said cDNA, such that the 3' end of the cDNA of the cDNA-mRNA hybrid comprises a sequence complementary to said template switching oligonucleotide, wherein the amplifier sequence and the template switching oligonucleotide contain the same sequence;

(e) contacting an amplification primer with said cDNA-mRNA hybrid under conditions that generate double stranded amplification products corresponding to the first strand cDNA synthesis, such that the double stranded cDNA amplification products comprise a double stranded RNA polymerase promoter; and

(f) incubating said double stranded cDNA amplification products comprising said double stranded RNA polymerase promoter under conditions that permit *in vitro* transcription to generate amplified RNA.

80. (new): A method of preparing a cDNA library from a collection of mRNA molecules comprising the steps of:

(a) providing a cDNA synthesis oligonucleotide comprising from the 5' end, an amplifier sequence, 3' to which is an RNA polymerase promoter operably linked to an RNA annealing region;

(b) contacting said cDNA synthesis oligonucleotide with the collection of mRNAs under conditions to allow annealing of said cDNA synthesis oligonucleotide to mRNA produce a cDNA-mRNA complex;

(c) incubating said cDNA-mRNA complex under conditions which permit template-dependent extension of said cDNA synthesis oligonucleotide to generate a cDNA-mRNA hybrid;

(d) contacting said cDNA-mRNA hybrid with a template switching oligonucleotide under conditions which permit template dependent extension of said cDNA of said hybrid, such that the 3' end of the cDNA of the cDNA-mRNA hybrid comprises a sequence complementary to said template switching oligonucleotide, wherein the amplifier sequence and the template switching oligonucleotide contain the same sequence;

(e) contacting a PCR primer with said cDNA-mRNA hybrid under conditions that generate double stranded amplification products corresponding to the first strand cDNA synthesis, such that the double stranded cDNA amplification products comprise a double stranded RNA polymerase promoter;

(f) incubating said double stranded cDNA amplification products comprising said double stranded RNA polymerase promoter under conditions that permit *in vitro* transcription to generate amplified RNA; and

(g) preparing a cDNA library from the amplified RNA.

81. (new): A method for performing subtractive hybridisation comprising the steps of:

(a) providing a cDNA synthesis oligonucleotide comprising from the 5' end, an amplifier sequence, 3' to which is an RNA polymerase promoter operably linked to an RNA annealing region;

(b) contacting the cDNA synthesis oligonucleotide with a collection of mRNAs under conditions to allow annealing of said cDNA synthesis oligonucleotide to mRNA in said RNA sample to produce a cDNA-mRNA complex;

(c) incubating said cDNA-mRNA hybrid with enzyme, dNTPs and buffer under conditions which permit template-dependent extension of said cDNA synthesis oligonucleotide to generate a cDNA-mRNA hybrid;

(d) contacting said cDNA-mRNA hybrid with a template switching oligonucleotide under conditions which permit template dependent extension of said cDNA of said hybrid, such that the 3' end of the cDNA of the cDNA-mRNA hybrid comprises a sequence complementary to said template switching oligonucleotide, wherein the amplifier sequence and the template switching oligonucleotide contain the same sequence;

(e) contacting an amplification primer with said cDNA-mRNA hybrid under conditions to generate double stranded amplification products corresponding to the first stand cDNA synthesis, such that the double stranded cDNA amplification products comprise a double stranded RNA polymerase promoter;

(f) incubating said double stranded cDNA amplification products comprising said double stranded RNA polymerase promoter under conditions that permit *in vitro* transcription to generate amplified RNA;

(g) contacting said amplified RNA with a single stranded nucleic acid population in the opposite sense to said amplified RNA;

(h) providing for the hybridisation of the sequences present in the amplified RNA and the single stranded nucleic acid population; and

(i) isolating the nucleic acid population that remains single stranded.

82. (new): A method for detecting the expression of a gene of interest comprising the steps of:

(a) providing a cDNA synthesis oligonucleotide comprising from the 5' end, an amplifier sequence, 3' to which is an RNA polymerase promoter operably linked to an RNA

annealing region, wherein the RNA annealing region comprises a sequence that is substantially homologous to the mRNA expressed by the gene of interest;

(b) contacting said cDNA synthesis oligonucleotide with a population of mRNAs in a cell or cell population under conditions to allow annealing of said cDNA synthesis oligonucleotide to mRNA to produce a cDNA-mRNA complex;

(c) incubating said cDNA-mRNA hybrid under conditions which permit template-dependent extension of said cDNA synthesis oligonucleotide to generate a cDNA-mRNA hybrid;

(d) contacting said cDNA-mRNA hybrid with a template switching oligonucleotide under conditions which permit template dependent extension of said cDNA of said hybrid, such that the 3' end of the cDNA of the cDNA-mRNA hybrid comprises a sequence complementary to said template switching oligonucleotide, wherein the amplifier sequence and the template switching oligonucleotide contain the same sequence;

(e) contacting an amplification primer with said cDNA-mRNA hybrid under conditions to generate double stranded amplification products corresponding to the first stand cDNA synthesis, such that the double stranded cDNA amplification products comprise a double stranded RNA polymerase promoter;

(f) incubating said double stranded cDNA amplification products comprising said double stranded RNA polymerase promoter under conditions that permit *in vitro* transcription to generate amplified RNA; and

(g) determining the presence or absence of amplified RNA, which amplified RNA is complementary to mRNA corresponding to the gene of interest.

83. (new): A kit for the amplification of RNA in a sample comprising:

(a) a cDNA synthesis oligonucleotide comprising from the 5' end, an amplifier sequence, 3' to which is an RNA polymerase promoter operably linked to an RNA annealing region;

(b) a template switching oligonucleotide that has the same sequence as the amplifier sequence; and

(c) an amplification primer that has the same sequence as the template switching oligonucleotide.

84. (new): The kit according to claim 83, wherein the kit further comprises in a separate container a reverse transcriptase, wherein the reverse transcriptase lacks RNaseH activity but retains wild-type polymerase activity.

85. (new): The kit according to claim 83 or 84, wherein the kit further comprises in a separate container an RNA polymerase specific to the RNA polymerase promoter of the cDNA synthesis oligonucleotide.

86. (new): The kit according to claim 85, wherein the RNA polymerase promoter is selected from a T7, T3 or SP6 RNA polymerase promoter.

87. (new): The kit according to claim 86, wherein the kit further comprises an amplification buffer and one or more amplification enzymes, wherein the amplification buffer and the amplification enzyme(s) are PCR amplification buffer and PCR amplification enzyme(s).